UBS Maintains Buy on McKesson, Raises Price Target to $1200

10/16/2026
Impact: 75
Healthcare

UBS analyst Kevin Caliendo has maintained a 'Buy' rating on McKesson (NYSE: MCK) and increased the price target from $1080 to $1200. This adjustment reflects positive expectations for the company's performance.

AI summary, not financial advice

Share: